MCID: EXN002
MIFTS: 61

Exanthem

Categories: Skin diseases, Infectious diseases

Aliases & Classifications for Exanthem

Summaries for Exanthem

MedlinePlus : 43 A rash is an area of irritated or swollen skin. Many rashes are itchy, red, painful, and irritated. Some rashes can also lead to blisters or patches of raw skin. Rashes are a symptom of many different medical problems. Other causes include irritating substances and allergies. Certain genes can make people more likely to get rashes. Contact dermatitis is a common type of rash. It causes redness, itching, and sometimes small bumps. You get the rash where you have touched an irritant, such as a chemical, or something you are allergic to, like poison ivy. Some rashes develop right away. Others form over several days. Although most rashes clear up fairly quickly, others are long-lasting and need long-term treatment. Because rashes can be caused by many different things, it's important to figure out what kind you have before you treat it. If it is a bad rash, if it does not go away, or if you have other symptoms, you should see your health care provider. Treatments may include moisturizers, lotions, baths, cortisone creams that relieve swelling, and antihistamines, which relieve itching.

MalaCards based summary : Exanthem, also known as exanthema, is related to aseptic meningitis and mumps. An important gene associated with Exanthem is CD40LG (CD40 Ligand), and among its related pathways/superpathways are ERK Signaling and Innate Immune System. The drugs Cetuximab and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and testes, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 An exanthem or exanthema (from Greek ἐξάνθημα exánthēma, \"a breaking out\") is a widespread rash... more...

Related Diseases for Exanthem

Diseases in the Exanthem family:

Bacterial Exanthem Viral Exanthem

Diseases related to Exanthem via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 349)
# Related Disease Score Top Affiliating Genes
1 aseptic meningitis 30.8 IL1RN NLRP3 TNF
2 mumps 29.9 CD40LG IL2 TNF
3 chikungunya 29.9 CD40LG IL6 TNF
4 meningoencephalitis 29.7 CD40LG CD79A IL6 TLR9
5 cryopyrin-associated periodic syndrome 29.6 CRP IL1RN IL6 NLRP3
6 pneumonia 29.2 CD40LG CRP IL6 TLR9 TNF
7 meningitis 29.2 CD40LG CRP IL6 NLRP3 TLR9 TNF
8 prostatitis 29.2 IL2 IL6 TNF
9 graft-versus-host disease 28.9 IL2 IL6 TNF
10 arthritis 28.9 IL1RN IL6 TNF TNFRSF1B
11 acquired immunodeficiency syndrome 28.6 CD40LG CD79A IL2 IL6 TNF
12 brucellosis 28.1 CD40LG CRP IL1RN IL2 IL6 TNF
13 myeloma, multiple 26.2 CD40LG CD79A CRP HRAS IL2 IL6
14 exanthema subitum 12.3
15 viral exanthem 12.1
16 bacterial exanthem 11.9
17 hand, foot and mouth disease 11.3
18 selective igg deficiency disease 11.1 CD40LG CD79A
19 c1q nephropathy 11.1 CD40LG CD79A
20 meningovascular neurosyphilis 11.0 CD40LG CD79A
21 alpha chain disease 11.0 CD40LG CD79A
22 brill-zinsser disease 11.0 CD40LG CD79A
23 exudative glomerulonephritis 11.0 CD40LG CD79A
24 cork-handlers' disease 11.0 CD40LG CD79A
25 salpingo-oophoritis 11.0 CD40LG CD79A
26 breast intraductal proliferative lesion 11.0 EGFR ERBB2
27 early yaws 11.0 CD40LG CD79A
28 ventilation pneumonitis 11.0 CD40LG CD79A
29 chronic interstitial cystitis 11.0 CD40LG CD79A
30 axillary adenitis 11.0 CD40LG CD79A
31 cryofibrinogenemia 11.0 CD40LG CD79A
32 contagious pustular dermatitis 11.0
33 severe cutaneous adverse reaction 11.0
34 sigmoid neoplasm 10.9 HRAS KRAS
35 schnitzler syndrome 10.9 CD40LG IL1RN NLRP3
36 transient neonatal thrombocytopenia 10.9 CD79A TRIM21
37 ocular toxoplasmosis 10.9 CD40LG CD79A TLR9
38 trichostrongyloidiasis 10.9 CD40LG CD79A
39 conjunctival disease 10.9 CD40LG CD79A NLRP3
40 subacute bacterial endocarditis 10.8 CD40LG CD79A
41 heterophyiasis 10.8 CD40LG CD79A
42 autoimmune disease of urogenital tract 10.8 CD40LG CD79A TLR9
43 immunoglobulin g deficiency 10.8 CD40LG CD79A
44 acute maxillary sinusitis 10.8 CD40LG CD79A CRP
45 hypersensitivity vasculitis 10.8 CD40LG CD79A CRP
46 pyelitis 10.8 CD40LG CD79A CRP
47 mature b-cell neoplasm 10.8 CD40LG CD79A TLR9
48 lung adenoid cystic carcinoma 10.8 EGFR HRAS KRAS
49 b cell deficiency 10.8 CD40LG CD79A TLR9
50 endocardium disease 10.8 CD40LG CD79A CRP

Graphical network of the top 20 diseases related to Exanthem:



Diseases related to Exanthem

Symptoms & Phenotypes for Exanthem

GenomeRNAi Phenotypes related to Exanthem according to GeneCards Suite gene sharing:

26 (show all 18)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.32 MTOR HRAS KALRN EGFR KRAS
2 Decreased viability GR00106-A-0 10.32 KRAS
3 Decreased viability GR00221-A-1 10.32 KRAS HRAS MTOR EGFR
4 Decreased viability GR00221-A-2 10.32 KRAS HRAS
5 Decreased viability GR00221-A-3 10.32 HRAS
6 Decreased viability GR00221-A-4 10.32 MTOR EGFR
7 Decreased viability GR00301-A 10.32 KALRN KRAS
8 Decreased viability GR00342-S-1 10.32 MTOR KALRN
9 Decreased viability GR00342-S-2 10.32 MTOR KALRN
10 Decreased viability GR00342-S-3 10.32 KALRN
11 Decreased viability GR00381-A-1 10.32 KALRN KRAS
12 Decreased viability GR00402-S-2 10.32 HRAS MTOR KALRN EGFR KRAS
13 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.73 ERBB2 HRAS MTOR HSPG2 KALRN EGFR
14 Decreased cell migration GR00055-A-1 9.72 MTOR EGFR KRAS HRAS KALRN
15 Decreased viability with paclitaxel GR00179-A-1 9.7 EGFR ERBB2 MTOR
16 Decreased viability with paclitaxel GR00179-A-2 9.7 MTOR
17 Decreased viability with paclitaxel GR00179-A-3 9.7 EGFR MTOR
18 Reduced mammosphere formation GR00396-S 9.23 TLR9 TNFRSF1B KRAS HRAS MTOR HSPG2

MGI Mouse Phenotypes related to Exanthem:

46 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.51 HRAS IL1RN IL2 ERBB2 HSPG2 KALRN
2 cardiovascular system MP:0005385 10.47 IL6 KRAS HRAS IL1RN IL2 ERBB2
3 cellular MP:0005384 10.44 IL6 KRAS IL1RN IL2 ERBB2 HSPG2
4 immune system MP:0005387 10.43 IL6 KRAS IL1RN IL2 HSPG2 TNFRSF1B
5 hematopoietic system MP:0005397 10.42 IL6 KRAS IL1RN IL2 HSPG2 TNFRSF1B
6 mortality/aging MP:0010768 10.41 IL6 HRAS KRAS IL1RN IL2 ERBB2
7 growth/size/body region MP:0005378 10.4 IL1RN HRAS IL6 IL2 KALRN ERBB2
8 integument MP:0010771 10.36 IL6 KRAS HRAS IL1RN ERBB2 HSPG2
9 digestive/alimentary MP:0005381 10.35 IL6 KRAS HRAS IL2 ERBB2 HSPG2
10 endocrine/exocrine gland MP:0005379 10.35 IL6 HRAS KRAS IL2 ERBB2 KALRN
11 nervous system MP:0003631 10.22 HRAS IL6 KALRN HSPG2 ERBB2 TNFRSF1B
12 liver/biliary system MP:0005370 10.15 IL6 IL2 HSPG2 TNFRSF1B EGFR TNF
13 craniofacial MP:0005382 10.13 ERBB2 HSPG2 HRAS TNFRSF1B EGFR TNF
14 muscle MP:0005369 10.11 IL6 KALRN ERBB2 HSPG2 TNFRSF1B EGFR
15 neoplasm MP:0002006 10.09 HRAS IL6 KRAS IL2 ERBB2 TNFRSF1B
16 renal/urinary system MP:0005367 10.06 IL6 HRAS KRAS TNFRSF1B EGFR CD40LG
17 reproductive system MP:0005389 10 IL1RN IL6 IL2 KALRN ERBB2 AREG
18 no phenotypic analysis MP:0003012 9.97 HRAS IL2 KALRN EGFR CD79A TNF
19 respiratory system MP:0005388 9.85 HRAS IL6 KRAS IL2 ERBB2 HSPG2
20 skeleton MP:0005390 9.73 IL6 HRAS KRAS IL1RN ERBB2 HSPG2
21 vision/eye MP:0005391 9.23 HSPG2 IL6 IL2 AREG TNFRSF1B EGFR

Drugs & Therapeutics for Exanthem

Drugs for Exanthem (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1176)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cetuximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 205923-56-4 56842117 2333
2
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1 51-21-8 3385
3
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
4
Menthol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2216-51-5 16666
5
Zinc Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 7440-66-6 23994
6
Zinc oxide Approved Phase 4,Phase 3,Not Applicable 1314-13-2
7
Vancomycin Approved Phase 4,Phase 3,Not Applicable 1404-90-6 441141 14969
8
Gabapentin Approved, Investigational Phase 4,Phase 2 60142-96-3 3446
9
gamma-Aminobutyric acid Approved, Investigational Phase 4,Phase 2 56-12-2 119
10
Piperacillin Approved Phase 4,Not Applicable 66258-76-2 43672
11
Sulbactam Approved Phase 4,Phase 2 68373-14-8
12
Azithromycin Approved Phase 4,Phase 3,Phase 2,Early Phase 1 83905-01-5 55185 447043
13
Piperaquine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 4085-31-8 5079497
14
Pyrimethamine Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2 58-14-0 4993
15
Sulfadoxine Approved, Investigational Phase 4,Phase 1,Phase 2 2447-57-6 17134
16
Ketorolac Approved Phase 4,Not Applicable 74103-06-3, 66635-83-4 3826
17
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
18
Travoprost Approved Phase 4 157283-68-6 5282226
19
Iron Approved Phase 4,Phase 2,Not Applicable 7439-89-6 23925
20
Cefazolin Approved Phase 4,Phase 3,Not Applicable 25953-19-9 656510 33255
21
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 75614-87-8, 51-45-6 774
22
Ketotifen Approved Phase 4,Phase 3 34580-14-8, 34580-13-7 3827
23
Adapalene Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 106685-40-9 60164
24
Benzoyl peroxide Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 94-36-0 7187
25
Clindamycin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 18323-44-9 29029
26
4-Aminopyridine Approved Phase 4 504-24-5 1727
27 Pinaverium Approved Phase 4 59995-65-2
28
Cefuroxime Approved Phase 4,Phase 2,Not Applicable 55268-75-2 5361202 5479529
29
Ciprofloxacin Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 85721-33-1 2764
30
Clarithromycin Approved Phase 4,Not Applicable 81103-11-9 84029
31
Moxifloxacin Approved, Investigational Phase 4,Phase 1 354812-41-2, 151096-09-2 152946
32
Penicillin G Approved, Vet_approved Phase 4 61-33-6 5904
33
Salmon Calcitonin Approved, Investigational Phase 4 47931-85-1 16129616
34
Tazobactam Approved Phase 4,Not Applicable 89786-04-9 123630
35
Nevirapine Approved Phase 4,Phase 3,Phase 1,Phase 2 129618-40-2 4463
36
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 53-03-2 5865
37
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 22916-47-8 4189
38 sodium fluoride Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7681-49-4
39
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 134678-17-4 60825
40
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 104987-11-3 445643 439492
41
Sunitinib Approved, Investigational Phase 4,Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102
42
Salicylic acid Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 69-72-7 338
43
Sorafenib Approved, Investigational Phase 4,Phase 2 284461-73-0 216239 406563
44
Clobetasol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 25122-46-7, 25122-41-2 32798 5311051
45
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 124-94-7 31307
46
Rifampicin Approved Phase 4,Phase 1,Phase 2 13292-46-1 5458213 5381226
47
Etanercept Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 185243-69-0
48
Etomidate Approved Phase 4 33125-97-2 36339 667484
49
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 2078-54-8 4943
50
Efavirenz Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 154598-52-4 64139

Interventional clinical trials:

(show top 50) (show all 2951)
# Name Status NCT ID Phase Drugs
1 Elmex Gel Efficacy in Preventing White Spot Lesions Unknown status NCT00268138 Phase 4 elmex gel
2 FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema Unknown status NCT01315990 Phase 4 FOLFIRI + Cetuximab
3 Trial Comparing Calmoseptine Ointment and Desitin Diaper Rash Paste in Diaper Dermatitis in Neonates and Infants Unknown status NCT02716415 Phase 4 Calmoseptine Ointment;Destin Maximum Strength 40% Zinc
4 Line Versus Spot Ablation in Persistent Atrial Fibrillation Unknown status NCT00196157 Phase 4
5 Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis Patients Unknown status NCT02605213 Phase 4 Vancomycin;Placebo
6 A Study to Evaluate the Efficacy and Safety of Flexible Dose of Quetiapine Fumarate (Seroquel) Switching From Other Drugs in the Treatment of Acute Manic Patients With Bipolar Disorder Unknown status NCT00837343 Phase 4 quetiapine fumarate tablet (Seroquel)
7 Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission Unknown status NCT01901666 Phase 4 Growth Hormone
8 Effects of Gabapentin Enacarbil on Arousals, Heart Rate, Blood Pressure and PLMs in Restless Legs Syndrome Unknown status NCT02424695 Phase 4 Gabapentin Enacarbil (GEn);Placebo
9 Effect of HIV and/or Active Tuberculosis on the Immune Responses to Trivalent Influenza Vaccine (TIV) in Adults Unknown status NCT01811823 Phase 4
10 Safety Study of Enterovirus 71 Vaccine in Children Aged 6-35 Months Old Unknown status NCT02806531 Phase 4
11 Piperacillin Sodium and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection Unknown status NCT01897831 Phase 4 xin te mie
12 Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection Unknown status NCT01760109 Phase 4 Piperacillin Sodium and Sulbactam Sodium
13 A Safety, Tolerability, Pharmacokinetic and Efficacy Study of Azithromycin Plus Piperaquine as Presumptive Treatment in Pregnant PNG Women Unknown status NCT02575755 Phase 4 Azithromycin plus piperaquine phosphate;Sulfadoxine-pyrimethamine
14 The Laser in Pseudoexfoliation (LIP) Study Unknown status NCT01704989 Phase 4 Prostagladin
15 Generic Travoprost Versus Brand Name Travoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Unknown status NCT02796560 Phase 4 Brand name travoprost;Generic travoprost
16 The Use of Iron Therapy for Patients With Anemia After Surgery Unknown status NCT01975272 Phase 4 Ferinject;Ferrous fumarate;Placebo for ferrous fumarate;Placebo for ferinject
17 The Use of Ceftaroline as Surgical Prophylaxis in Surgery With Risk of MRSA Infection Unknown status NCT02307006 Phase 4 Ceftaroline;Cefazolin / Vancomycin
18 Ketotifen as a Treatment for Vascular Leakage During Dengue Fever Unknown status NCT02673840 Phase 4 Ketotifen;Placebo
19 Pilot Study of Tolerability and Effectivity of Two Combination Topical Acne Products Unknown status NCT02731105 Phase 4 Acnatac® Gel left face;Epiduo® Gel right face;Acnatac® Gel right face;Epiduo® Gel left face
20 Safety and Tolerability of Acanya Gel in Combination With Atralin Gel for Acne Vulgaris Unknown status NCT01448733 Phase 4 Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning with with tretinoin 0.05% gel in the evening
21 A Study Comparing Combination Clindamycin Phosphate/Tretinoin Gel Alone Versus With Benzoyl Peroxide Foaming Cloths for Facial Acne Unknown status NCT01422785 Phase 4 clindamycin phosphate 1.2%/tretinoin 0.025% gel alone;clindamycin phosphate 1.2%/tretinoin 0.025% gel plus benzoyl peroxide 6% foaming cloths
22 Clinical Study to Evaluate the Efficacy of Topical Medications Containing Benzoyl Peroxide and Sulfur in the Regression in the Short Time (24 Hours) of Moderate Acne Vulgaris Grade II (Pimples) Unknown status NCT01260571 Phase 4 Benzoyl peroxide and sulfur
23 Resistance Training and Amino Pyridine in Multiple Sclerosis Unknown status NCT02143167 Phase 4 SR-fampridine;Placebo
24 Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE) Unknown status NCT01553032 Phase 4 Erbitux®
25 Targeted Indoor Residual Spraying Against Malaria Unknown status NCT02556242 Phase 4
26 Pinaverium Bromide in Post-cholecystectomy Sphincter of Oddi Dysfunction Unknown status NCT02833103 Phase 4 Danshu Capsules;Pinaverium Bromide
27 Procalcitonin as a Marker of Antibiotic Therapy in Patients With Lower Respiratory Tract Infections Unknown status NCT02171338 Phase 4
28 Clinical Study to Evaluate the Efficacy and Safety of Two Marketed Investigational Products in Children With Diaper Rash Completed NCT00219466 Phase 4
29 Evaluation of 2 Interferon γ Assays in the Diagnosis of Latent Tuberculosis in HIV-infected Patients.ANRS EP 40 QUANTI SPOT Completed NCT00647205 Phase 4
30 MI Varnish for the Prevention of White Spot Lesions Completed NCT03446690 Phase 4 MI Varnish
31 Remineralisation of White Spot Lesions by Elmex® gelée in Post-orthodontic Patients Completed NCT01329731 Phase 4 elmex® gelée;negative control (placebo)
32 Study of Nevirapine and Prednisone to Determine the Safety and Effectiveness in Preventing Nevirapine Associated Rash in Human Immunodeficiency Virus (HIV) Infected Patients Completed NCT02184299 Phase 4 Nevirapine;Prednisone
33 Lumefantrine in Venous Plasma Versus Dried Capillary Blood Spot Completed NCT02742285 Phase 4 Artemether + lumefantrine
34 Therapeutic Effect of Two Fluoride Varnishes on White Spot Lesions: a Clinical Study Completed NCT00723515 Phase 4 sodium fluoride;sodium fluoride calcium fluoride
35 MI Varnish and MI Paste Plus in a Caries Prevention and Remineralization Study Completed NCT02424097 Phase 4 CPP-ACP 5% sodium fluoride varnish & 900ppm fluoride paste;1,100pm F-toothpaste and 0.5%NaF rinse
36 Caries-preventive Effect of a Dentifrice Containing 5,000 Ppm Fluoride in Orthodontic Patients Completed NCT01768390 Phase 4
37 Genotype Based Personalized Prescription of Nevirapine Completed NCT00986063 Phase 4
38 Study to Evaluate the Effect of a Nu Skin Product and Device for Brown Spots Completed NCT01149876 Phase 4 Tretinoin cream 0.05
39 Prospective Two-Year Study to Assess Miconazole Nitrate Resistance in Neonates and Infants Completed NCT00702507 Phase 4 0.25 % Miconazole Nitrate Ointment
40 Selection of Immunosuppression in Kidney Transplant Recipients Depending on Pre-transplant Donor-specific T-cell Reactivity. Completed NCT01195194 Phase 4 PRE-TRANSPLANT (PRE=before)
41 Comparison of the Effect of Fluoride Remineralizer Gel and Foam Completed NCT02490592 Phase 4
42 Efficacy of Pentoxifylline on Chronic Kidney Disease Completed NCT00155246 Phase 4 pentoxifylline (drug)
43 Subcutaneous Amifostine Safety Study Completed NCT00158041 Phase 4 Amifostine administered subcutaneously
44 Prospective Randomized Controlled Treatment Trial for Chronic Central Serous Chorioretinopathy Completed NCT01797861 Phase 4
45 Robust Antibody and Cytokine Response to Hepatitis B Vaccine Among Not-in-treatment Patients With Chronic Hepatitis C:An Open-label Control Study in China Completed NCT02898922 Phase 4
46 SIGnificance of Routine Hysteroscopy Prior to a First 'in Vitro Fertilization'(IVF) Treatment Cycle Completed NCT01242852 Phase 4
47 Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients Completed NCT01402089 Phase 4 Sunitinib;Erlotinib;Midazolam;Caffeine
48 A Study of Vacyless® Versus Valtrex® in Patients With Herpes Zoster Completed NCT02152800 Phase 4 valacyclovir hydrocholoride
49 Impact of Dihydroartemisinin-piperaquine Plus Primaquine on Malaria Transmission in Lampung Province, Sumatra Completed NCT01389557 Phase 4 Dihydroartemisinin-piperaquine with primaquine
50 Bipolar Study in Adults at Least 18 Years of Age Completed NCT00067938 Phase 4 lamotrigine

Search NIH Clinical Center for Exanthem

Cochrane evidence based reviews: exanthema

Genetic Tests for Exanthem

Anatomical Context for Exanthem

MalaCards organs/tissues related to Exanthem:

41
Skin, Eye, Testes, Breast, Kidney, Lung, Bone

Publications for Exanthem

Articles related to Exanthem:

(show top 50) (show all 267)
# Title Authors Year
1
Ten-year-old traveller with fever and an exceptional exanthem. ( 29314384 )
2018
2
Acral-accentuated exanthem in an infant with parechovirus meningitis. ( 29205494 )
2018
3
What's in a Rash? Viral Exanthem Versus CBRNE Exposure: Teleconsultation Support for Two Special Forces Soldiers With Diffuse Rash in an Austere Environment. ( 29889970 )
2018
4
Asymmetric periflexural exanthem: not a distinctive disease of childhood. ( 29582621 )
2018
5
Ten-year-old traveller with fever and an exceptional exanthem. ( 29314380 )
2018
6
50 Years Ago in The Journal of Pediatrics: Atypical Exanthem after Exposure to Natural Measles: Eleven Cases in Children Previously Inoculated with Killed Vaccine. ( 29389454 )
2018
7
Exanthem, Fieber und Arthralgien bei einer 19-jAohrigen Patientin. ( 29645383 )
2018
8
Unilateral laterothoracic exanthem. ( 28754336 )
2017
9
Can Unilateral Pityriasis Rosea be Considered a Form of Superimposed Lateralized Exanthem? ( 28764276 )
2017
10
TherapierefraktAores Exanthem eines sechs Monate alten SAouglings. ( 29228485 )
2017
11
Superimposed lateralized exanthem in a 30-year-old woman. ( 28893877 )
2017
12
Image Gallery: Flagellate bullous exanthem in chikungunya. ( 29052889 )
2017
13
Epstein-Barr virus exanthem in an adult patient with myelodysplastic syndrome. ( 29274098 )
2017
14
Exanthem und Ekzem bei einem anderthalbjAohrigen Jungen. ( 28214315 )
2017
15
Dengue-Fieber und die Differenzialdiagnosen zu Exanthem, Fieber und Kopfschmerzen nach Fernreise. ( 28140551 )
2017
16
IgA multiple myeloma in a patient with an IgG pemphigus foliaceus-like exanthem. ( 28856664 )
2017
17
Assessment of histopathological features of maculopapular viral exanthem and drug-induced exanthem. ( 28914958 )
2017
18
Acute localized exanthem due to Coxsackievirus A4. ( 28956547 )
2017
19
Asymmetric periflexural/unilateral laterothoracic exanthem related to parvovirus B19 infection: An adult carrier of A9-globin thalassaemia gene mutation in Hong Kong. ( 29896828 )
2016
20
Image Gallery: A case of unilateral laterothoracic exanthem. ( 27996140 )
2016
21
Exanthem subitum (human herpesvirus-6 reactivation) after autologous stem cell transplantation. ( 26918962 )
2016
22
"Tache noire": diagnostic clue in a febrile exanthem. ( 28038854 )
2016
23
Urticarial exanthem associated with Capnocytophaga canimorsus bacteremia after a dog bite. ( 27051842 )
2016
24
Lateralized exanthem mimicking figurate inflammatory dermatosis of infancy after methimazole therapy. ( 27272160 )
2016
25
Monitoring of human herpesviruses-6 and -7 DNA in saliva samples during the acute and convalescent phases of exanthem subitum. ( 27648817 )
2016
26
Eruptive hypomelanosis in a child, a new viral exanthem. ( 26728822 )
2016
27
Anogenital allergic contact dermatitis caused by methylchloroisothiazolinone, methylisothiazolinone and topical clotrimazole with subsequent generalized exanthem triggered by oral fluconazole. ( 27040872 )
2016
28
A mini-epidemic of eruptive hypomelanosis in three children of the same family; the first piece of epidemiological evidence for an infectious cause of a novel paraviral exanthem. ( 27038439 )
2016
29
Coxsackievirus A6 Polymorphic Exanthem in Israeli Children. ( 26463513 )
2016
30
Stammbetontes Exanthem mit Allgemeinsymptomatik. ( 26972204 )
2016
31
Pityriasis Rosea, Gianotti-Crosti Syndrome, Asymmetric Periflexural Exanthem, Papular-Purpuric Gloves and Socks Syndrome, Eruptive Pseudoangiomatosis, and Eruptive Hypomelanosis: Do Their Epidemiological Data Substantiate Infectious Etiologies? ( 27103975 )
2016
32
Unilateral Exanthem. ( 26120168 )
2015
33
Purpuric exanthem caused by Ross River virus infection. ( 25551310 )
2015
34
Unilateral Laterothoracic Exanthem. ( 26187001 )
2015
35
Localized exanthem due to echovirus 9. ( 25919440 )
2015
36
Febrile Exanthem with Hyperferritinemia. ( 26705442 )
2015
37
Aminopenicillin-associated exanthem: lymphocyte transformation testing revisited. ( 25323308 )
2014
38
Eruptive hypomelanosis: a novel exanthem associated with viral symptoms in children. ( 25229328 )
2014
39
Superimposed lateralized exanthem of childhood: report of a case related to adenovirus infection. ( 24635078 )
2014
40
Vesiculobullous viral exanthem due to chikungunya in an infant. ( 25593800 )
2014
41
Unilateral laterothoracic or asymmetric periflexural exanthem: is time to change the name of the disease? ( 25267301 )
2014
42
Black heel (talon noir) associated with a viral exanthem. ( 24222298 )
2013
43
Acetaminophen-induced exanthem of the breasts. ( 22838093 )
2012
44
Unilateral laterothoracic exanthem. ( 21989468 )
2012
45
Generalized purpuric drug exanthem with hemorrhagic plaques following bendamustine chemotherapy in a patient with B-prolymphocytic leukemia. ( 22290027 )
2012
46
Febrile illness with papular and vesicular exanthem and ulceronecrotic plaques. ( 23106676 )
2012
47
Histopathology of measles exanthem: a case with characteristic features and eosinophils. ( 22725635 )
2012
48
Gianotti-Crosti syndrome, pityriasis rosea, asymmetrical periflexural exanthem, unilateral mediothoracic exanthem, eruptive pseudoangiomatosis, and papular-purpuric gloves and socks syndrome: a brief review and arguments for diagnostic criteria. ( 24470919 )
2012
49
A challenging case: Symmetrical drug related intertriginous and flexural exanthem, fixed drug eruption, or both? ( 22082466 )
2011
50
Drug-induced exanthem following dabigatran. ( 21881034 )
2011

Variations for Exanthem

Expression for Exanthem

Search GEO for disease gene expression data for Exanthem.

Pathways for Exanthem

Pathways related to Exanthem according to GeneCards Suite gene sharing:

(show top 50) (show all 97)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.93 AREG CD40LG EGFR ERBB2 HRAS HSPG2
2
Show member pathways
13.87 CD40LG CD79A CRP EGFR ERBB2 HRAS
3
Show member pathways
13.75 CD40LG EGFR ERBB2 HRAS IL1RN IL2
4
Show member pathways
13.65 AREG CRP EGFR ERBB2 HRAS IL2
5
Show member pathways
13.54 CD40LG CD79A EGFR ERBB2 HRAS KRAS
6
Show member pathways
13.52 AREG EGFR ERBB2 HRAS IL2 IL6
7
Show member pathways
13.41 AREG CD79A EGFR ERBB2 HRAS IL2
8
Show member pathways
13.36 AREG EGFR ERBB2 HRAS IL2 IL6
9
Show member pathways
13.31 AREG CD40LG EGFR ERBB2 HRAS IL2
10
Show member pathways
13.28 CD40LG EGFR ERBB2 HRAS IL1RN IL2
11
Show member pathways
13.14 AREG EGFR HRAS IL2 IL6 KRAS
12
Show member pathways
13.08 AREG CD40LG EGFR ERBB2 HRAS IL2
13
Show member pathways
13.07 AREG CD79A EGFR HRAS HSPG2 IL2
14
Show member pathways
13.02 CD40LG CD79A EGFR HRAS KRAS TNF
15
Show member pathways
12.98 HRAS IL2 IL6 KRAS MTOR TNF
16
Show member pathways
12.97 CD40LG HRAS IL2 IL6 TNF TNFRSF1B
17
Show member pathways
12.97 EGFR ERBB2 HRAS IL6 KRAS MTOR
18
Show member pathways
12.97 AREG EGFR ERBB2 HRAS KRAS MTOR
19
Show member pathways
12.95 HRAS IL6 KRAS TNF TNFRSF1B
20
Show member pathways
12.94 AREG EGFR ERBB2 HRAS IL2 IL6
21
Show member pathways
12.9 CD79A HRAS IL2 KRAS TLR9 TNF
22 12.9 EGFR ERBB2 HRAS IL2 IL6 KRAS
23
Show member pathways
12.87 AREG EGFR ERBB2 HRAS KRAS MTOR
24
Show member pathways
12.86 IL2 IL6 NLRP3 TLR9 TNF
25
Show member pathways
12.86 EGFR ERBB2 HRAS IL6 KRAS MTOR
26 12.85 AREG EGFR ERBB2 HRAS KRAS TNF
27
Show member pathways
12.83 EGFR ERBB2 HRAS KRAS MTOR
28
Show member pathways
12.81 CD79A EGFR ERBB2 HRAS KRAS MTOR
29
Show member pathways
12.75 CD40LG EGFR HRAS KRAS TNF TNFRSF1B
30
Show member pathways
12.71 EGFR HRAS IL2 IL6 MTOR TNF
31
Show member pathways
12.65 HRAS HSPG2 IL6 KRAS MTOR TNF
32
Show member pathways
12.64 EGFR ERBB2 HRAS IL2 IL6 KRAS
33 12.62 EGFR ERBB2 HRAS KRAS MTOR
34
Show member pathways
12.62 AREG CD40LG EGFR IL2 IL6 TLR9
35
Show member pathways
12.61 AREG EGFR ERBB2 HRAS KRAS MTOR
36
Show member pathways
12.59 CD40LG TLR9 TNF TNFRSF1B
37 12.59 CD40LG CD79A IL1RN IL2 TLR9 TNF
38
Show member pathways
12.58 ERBB2 HRAS IL1RN KRAS MTOR
39
Show member pathways
12.53 AREG EGFR ERBB2 HRAS KRAS MTOR
40 12.52 HRAS IL2 IL6 KRAS TNF
41
Show member pathways
12.52 EGFR ERBB2 HRAS KRAS MTOR TNF
42
Show member pathways
12.49 EGFR ERBB2 HRAS IL2 KRAS MTOR
43
Show member pathways
12.46 CD40LG HRAS IL2 IL6 KRAS TNF
44
Show member pathways
12.42 HRAS HSPG2 KRAS MTOR
45
Show member pathways
12.4 CRP IL2 IL6 TNF
46
Show member pathways
12.39 EGFR ERBB2 HRAS KRAS
47
Show member pathways
12.34 IL2 IL6 TLR9 TNF
48
Show member pathways
12.32 AREG EGFR HRAS KRAS
49
Show member pathways
12.32 EGFR HRAS IL1RN IL6 TNF
50 12.27 EGFR IL6 KRAS TLR9 TNF

GO Terms for Exanthem

Cellular components related to Exanthem according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intracellular GO:0005622 9.86 AREG CD40LG EGFR ERBB2 IL1RN IL2
2 extracellular region GO:0005576 9.7 CD40LG CRP EGFR HSPG2 IL1RN IL2
3 membrane raft GO:0045121 9.55 CD79A EGFR KRAS TNF TNFRSF1B
4 extracellular space GO:0005615 9.32 AREG CD40LG CRP EGFR HSPG2 IL1RN

Biological processes related to Exanthem according to GeneCards Suite gene sharing:

(show all 41)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.99 EGFR ERBB2 HRAS TNF
2 cytokine-mediated signaling pathway GO:0019221 9.99 IL1RN IL2 IL6 KRAS TNF TNFRSF1B
3 cell surface receptor signaling pathway GO:0007166 9.98 CD79A EGFR ERBB2 HRAS TNFRSF1B
4 MAPK cascade GO:0000165 9.95 EGFR ERBB2 HRAS IL2 KRAS TNF
5 positive regulation of protein kinase B signaling GO:0051897 9.92 EGFR ERBB2 MTOR TNF
6 cellular response to lipopolysaccharide GO:0071222 9.9 IL6 NLRP3 TNF TNFRSF1B
7 defense response to Gram-positive bacterium GO:0050830 9.87 CRP IL6 NLRP3 TNF
8 positive regulation of cell growth GO:0030307 9.85 EGFR ERBB2 IL2
9 positive regulation of inflammatory response GO:0050729 9.85 EGFR IL2 TLR9
10 positive regulation of JNK cascade GO:0046330 9.85 HRAS TLR9 TNF
11 positive regulation of translation GO:0045727 9.85 ERBB2 IL6 MTOR
12 positive regulation of MAPK cascade GO:0043410 9.85 EGFR ERBB2 HRAS IL6 TLR9 TNFRSF1B
13 positive regulation of T cell proliferation GO:0042102 9.84 CD40LG IL2 IL6
14 positive regulation of epithelial cell proliferation GO:0050679 9.84 EGFR ERBB2 HRAS
15 cellular response to growth factor stimulus GO:0071363 9.83 EGFR ERBB2 TNFRSF1B
16 epidermal growth factor receptor signaling pathway GO:0007173 9.83 AREG EGFR HRAS KRAS
17 cellular response to amino acid stimulus GO:0071230 9.82 EGFR MTOR TNF
18 positive regulation of interleukin-6 production GO:0032755 9.81 IL6 TLR9 TNF
19 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.81 EGFR TLR9 TNF
20 positive regulation of smooth muscle cell proliferation GO:0048661 9.8 EGFR IL6 MTOR TNF
21 response to glucocorticoid GO:0051384 9.8 AREG IL1RN IL6 KRAS TNF
22 positive regulation of interferon-gamma production GO:0032729 9.79 HRAS IL2 TNF
23 positive regulation of DNA replication GO:0045740 9.78 AREG EGFR HRAS
24 positive regulation of gene expression GO:0010628 9.76 CRP ERBB2 HRAS IL6 KRAS MTOR
25 ERBB2 signaling pathway GO:0038128 9.73 EGFR ERBB2 HRAS KRAS
26 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.73 CD40LG IL6 KRAS